Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
It is a muscle relaxant with direct action on skeletal muscle. Oral administration for the symptomatic relief of severe chronic spasticity. Intravenous administration for the treatment of malignant hyperthermia.
It is excreted in breast milk in a very small concentration (Fricker 1998), much lower than the dose used in newborns and infants, and which would result in lower plasma levels than others that have been measured by placental transfer without side effects in newborns. (Fricker 1998, Shime 1988)
Dantrolene has been used in the neonatal period. (Tsutsumi 2021, Aguilar 1986)
The most common side effects are drowsiness, weakness, dizziness, malaise, fatigue, and diarrhea.
Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable, especially during the neonatal period and in the event of prematurity.